Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PREVENTION AND TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE - THE OLDAND THE NEW - A REPORT FROM THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP (ECOG)
Autore:
LAZARUS HM; VOGELSANG GB; ROWE JM;
Indirizzi:
CASE WESTERN RESERVE UNIV,UNIV HOSP CLEVELAND,IRELAND CANC CTR,DEPT MED,11100 EUCLID AVE CLEVELAND OH 44106 JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ONCOL CTR BALTIMORE MD 21205 UNIV ROCHESTER,STRONG MEM HOSP ROCHESTER NY 14642
Titolo Testata:
Bone marrow transplantation
fascicolo: 6, volume: 19, anno: 1997,
pagine: 577 - 600
SICI:
0268-3369(1997)19:6<577:PATOAG>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; T-CELL DEPLETION; NECROSIS-FACTOR-ALPHA; MINOR HISTOCOMPATIBILITY ANTIGENS; RECEPTOR MONOCLONAL-ANTIBODY; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; HLA-IDENTICAL SIBLINGS; SEVERE APLASTIC-ANEMIA; SEVERE COMBINED IMMUNODEFICIENCY;
Keywords:
GRAFT-VERSUS-HOST DISEASE; CYCLOSPORINE; PREDNISONE; TRANSPLANTATION; CYTOKINES; MONOCLONAL ANTIBODIES;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
373
Recensione:
Indirizzi per estratti:
Citazione:
H.M. Lazarus et al., "PREVENTION AND TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE - THE OLDAND THE NEW - A REPORT FROM THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP (ECOG)", Bone marrow transplantation, 19(6), 1997, pp. 577-600

Abstract

There have been many advances in the prevention and treatment of GVHD, including cyclosporine, FK506, and combination therapies, This syndrome, however, continues to account for significant morbidity and mortality after allogeneic transplantation. With the expanded use of matched unrelated as well as mismatched related donors, the increase in incidence and severity of GVHD poses a new clinical challenge, Many of thenewer agents discussed in this paper may have a role in the future astherapy for acute GVHD, The evaluation of these new agents and the approach to be taken is hampered by the realization that most patients have received and are relatively refractory to standard therapies, Clinical trials must be performed earlier in the course of the syndrome toestablish the role of these compounds, Newer strategies are likely toinclude the use of sequential therapy directed at blocking endogenouscytokines followed by blocking alloreactive donor cells, and immunologic advances such as the induction of tolerance, What impact, if any, such therapy may have on amelioration of a graft-versus-leukemia effect remains unknown.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 19:34:28